Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465–475

Article  CAS  PubMed  Google Scholar 

Moore PA, Belvedere O, Orr A et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260–263. https://doi.org/10.1126/science.285.5425.260

Article  CAS  PubMed  Google Scholar 

Shu HB, Hu WH, Johnson H (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65:680–683. https://doi.org/10.1002/jlb.65.5.680

Article  CAS  PubMed  Google Scholar 

Gross JA, Johnston J, Mudri S et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. https://doi.org/10.1038/35010115

Article  PubMed  Google Scholar 

Mukhopadhyay A, Ni J, Zhai Y et al (1999) Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-jun NH2- terminal kinase. J Biol Chem. https://doi.org/10.1074/jbc.274.23.15978

Article  PubMed  Google Scholar 

Schneider P, Mackay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756. https://doi.org/10.1084/jem.189.11.1747

Article  CAS  PubMed  PubMed Central  Google Scholar 

Batten M, Groom J, Cachero TG et al (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. https://doi.org/10.1084/jem.192.10.1453

Article  PubMed  PubMed Central  Google Scholar 

Vincent FB, Morand EF, Schneider P et al (2014) The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10:365–373

Article  CAS  PubMed  Google Scholar 

Mackay F, Leung H (2006) The role of the BAFF/APRIL system on T cell function. Semin Immunol 18:284–289

Article  CAS  PubMed  Google Scholar 

Vincent FB, Saulep-Easton D, Figgett WA et al (2013) The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. https://doi.org/10.1016/j.cytogfr.2013.04.003

Article  PubMed  PubMed Central  Google Scholar 

Hahne M, Kataoka T, Schröter M et al (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. https://doi.org/10.1084/jem.188.6.1185

Article  PubMed  PubMed Central  Google Scholar 

Mackay F, Schneider P, Rennert P et al (2003) BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231–264

Article  CAS  PubMed  Google Scholar 

Ng LG, Mackay CR, Mackay F (2005) The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 42:763–772

Article  CAS  PubMed  Google Scholar 

López-Fraga M, Fernández R, Albar JP et al (2001) Biologically active APRIL is secreted following intracellular processing in the golgi apparatus by furin convertase. EMBO Rep. https://doi.org/10.1093/embo-reports/kve198

Article  PubMed  PubMed Central  Google Scholar 

Moreaux J, Legouffe E, Jourdan E et al (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. https://doi.org/10.1182/blood-2003-06-1984

Article  PubMed  Google Scholar 

Novak AJ, Bram RJ, Kay NE et al (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. https://doi.org/10.1182/blood-2002-02-0558

Article  PubMed  Google Scholar 

Ohmatsu H, Sugaya M, Miyagaki T et al (2012) BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma. Br J Dermatol. https://doi.org/10.1111/j.1365-2133.2012.10998.x

Article  PubMed  Google Scholar 

Neri P, Kumar S, Fulciniti MT et al (2007) Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-07-0753

Article  PubMed  Google Scholar 

Schiff M, Combe B, Dörner T et al (2015) Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: Results of a randomised, double-blind, placebo-controlled, phase 3 study. RMD Open. https://doi.org/10.1136/rmdopen-2014-000037

Article  PubMed  PubMed Central  Google Scholar 

Tai YT, Li XF, Breitkreutz I et al (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-06-0190

Article  PubMed  Google Scholar 

Kim SJ, Lee SJ, Choi IY et al (2008) Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol. https://doi.org/10.1111/j.1600-0609.2008.01099.x

Article  PubMed  Google Scholar 

Miao YR, Thakkar K, Cenik C et al (2022) Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. J Exp Med. https://doi.org/10.1084/jem.20220214

Article  PubMed  PubMed Central  Google Scholar 

Haiat S, Billard C, Quiney C et al (2006) Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118:281–292

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun B, Li L, Xu M et al (2016) Significance of BAFF/APRIL expression and their receptors in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. https://doi.org/10.1097/MPH.0000000000000549

Article  PubMed  PubMed Central  Google Scholar 

Claudio JO, Masih-Khan E, Tang H et al (2002) A molecular compendium of genes expressed in multiple myeloma. Blood. https://doi.org/10.1182/blood-2002-01-0008

Article  PubMed  Google Scholar 

Briones J, Timmerman JM, Hilbert DM et al (2002) BLyS and BLyS receptor expression in non-Hodgkin’s lymphoma. Exp Hematol. https://doi.org/10.1016/S0301-472X(01)00774-3

Article  PubMed  Google Scholar 

Mackay F, Tangye SG (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4:347–354

Article  CAS  PubMed  Google Scholar 

Raje NS, Moreau P, Terpos E et al (2017) Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. https://doi.org/10.1111/bjh.14483

Article  PubMed  Google Scholar 

Raje NS, Faber EA, Richardson PG et al (2016) Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-0201

Article  PubMed  Google Scholar 

Bolkun L, Lemancewicz D, Jablonska E et al (2015) The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features. Ann Hematol. https://doi.org/10.1007/s00277-014-2178-x

Article  PubMed